Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims at the formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. Ropidoxuridine is used to sensitize rapidly growing cancer cells and selective histone deacetylase inhibitors to sensitize cancer cells.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Shuttle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2023